Biologics represent a breakthrough in the management of airway diseases, offering precision treatments that target specific immune pathways. This special issue, Biologics for Airway Diseases: From ...

Nearly 30 million adults in the U.S. have obstructive sleep apnea (OSA)—and many don't even know it. If you've been waking up ...

Mount Sinai researchers have created an analytic tool using machine learning that can predict cardiovascular disease risk in ...

Mount Sinai researchers have created an analytic tool using machine learning that can predict cardiovascular disease risk in millions of patients with ...

Mount Sinai researchers have created an analytic tool using machine learning that can predict cardiovascular disease risk in patients with obstructive sleep apnea ...

AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...

Among patients with OSA, the risk for severe COVID-19 does not differ among those who are adherent vs nonadherent to CPAP.

New research to be presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May) shows that those ...

An estimated 1 billion people between the ages of 30 and 69 across the globe suffer from sleep apnea, particularly ...

Treatment management guided by the use of a noninvasive device to monitor fluid accumulation in the lungs substantially reduced hospitalizations and deaths among patients with heart failure with ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...

Columnist Kylene Henderson likes to think of her husband, Donnie, as Iron Man, given his use of supplemental oxygen to thrive ...